Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Analysts at Leerink Swann upped their FY2017 earnings per share estimates for Alexion Pharmaceuticals in a report released on Thursday. Leerink Swann analyst now anticipates that the biopharmaceutical company will post earnings of $5.05 per share for the year, up from their prior estimate of $5.02. Leerink Swann has a “Buy” rating and a $169.00 price objective on the stock. Leerink Swann also issued estimates for Alexion Pharmaceuticals’ Q4 2017 earnings at $1.34 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same period last year, the firm posted $1.23 EPS. The company’s revenue was up 7.5% on a year-over-year basis.
Alexion Pharmaceuticals (ALXN) opened at $120.35 on Friday. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $27,282.78, a P/E ratio of 53.73, a PEG ratio of 1.02 and a beta of 1.18. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34.
A number of hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue increased its stake in Alexion Pharmaceuticals by 510.1% in the fourth quarter. State of Alaska Department of Revenue now owns 25,990 shares of the biopharmaceutical company’s stock worth $3,106,000 after purchasing an additional 21,730 shares during the period. Moody National Bank Trust Division purchased a new stake in Alexion Pharmaceuticals in the fourth quarter worth $392,000. Schwab Charles Investment Management Inc. increased its stake in Alexion Pharmaceuticals by 6.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 906,805 shares of the biopharmaceutical company’s stock worth $108,445,000 after purchasing an additional 56,472 shares during the period. Creative Planning increased its stake in Alexion Pharmaceuticals by 72.2% in the fourth quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock worth $3,321,000 after purchasing an additional 11,642 shares during the period. Finally, Gateway Investment Advisers LLC increased its stake in Alexion Pharmaceuticals by 2.0% in the fourth quarter. Gateway Investment Advisers LLC now owns 143,199 shares of the biopharmaceutical company’s stock worth $17,125,000 after purchasing an additional 2,861 shares during the period. Institutional investors and hedge funds own 94.27% of the company’s stock.
In related news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.35% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/19/fy2017-earnings-forecast-for-alexion-pharmaceuticals-inc-issued-by-leerink-swann-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.